Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in atypical hemolytic uremic syndrome (aHUS)
CTR20211368Phase 3Active
- Sponsor
- Roche
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Roche. Started May 2022; status: active.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on CTR20211368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211368.